全文获取类型
收费全文 | 419篇 |
免费 | 15篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 14篇 |
妇产科学 | 6篇 |
基础医学 | 37篇 |
口腔科学 | 5篇 |
临床医学 | 42篇 |
内科学 | 115篇 |
皮肤病学 | 4篇 |
神经病学 | 8篇 |
特种医学 | 88篇 |
外科学 | 75篇 |
综合类 | 14篇 |
预防医学 | 14篇 |
眼科学 | 6篇 |
药学 | 22篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 5篇 |
2018年 | 2篇 |
2016年 | 2篇 |
2015年 | 6篇 |
2014年 | 4篇 |
2013年 | 8篇 |
2012年 | 7篇 |
2011年 | 9篇 |
2010年 | 12篇 |
2009年 | 13篇 |
2008年 | 9篇 |
2007年 | 10篇 |
2006年 | 34篇 |
2005年 | 17篇 |
2004年 | 11篇 |
2003年 | 11篇 |
2002年 | 13篇 |
2001年 | 17篇 |
2000年 | 10篇 |
1999年 | 7篇 |
1998年 | 14篇 |
1997年 | 6篇 |
1996年 | 19篇 |
1995年 | 15篇 |
1994年 | 16篇 |
1993年 | 7篇 |
1992年 | 10篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 19篇 |
1988年 | 15篇 |
1987年 | 14篇 |
1986年 | 14篇 |
1985年 | 16篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 3篇 |
1981年 | 8篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 4篇 |
1976年 | 2篇 |
1975年 | 3篇 |
1955年 | 2篇 |
1954年 | 2篇 |
1950年 | 2篇 |
1943年 | 2篇 |
排序方式: 共有460条查询结果,搜索用时 11 毫秒
101.
Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation 总被引:20,自引:7,他引:20
Shapiro RS; McClain K; Frizzera G; Gajl-Peczalska KJ; Kersey JH; Blazar BR; Arthur DC; Patton DF; Greenberg JS; Burke B 《Blood》1988,71(5):1234-1243
B cell lymphoproliferative disorders (BLPD) developed in eight patients following bone marrow transplantation (BMT) for leukemia (five patients) or immunodeficiency (three patients). Recipients of T depleted marrow from a mismatched donor were at particularly high risk of this complication. Six of 25 (24%) recipients of mismatched T depleted bone marrow developed BLPD. In contrast, none of 47 matched T depleted transplants, one of ten (10%) who received non-depleted marrow from an unrelated donor, and only one of 424 matched non-depleted transplants were associated with BLPD. Epstein-Barr virus (EBV) specific serology and DNA hybridization studies demonstrating five to 50 copies of EBV genome/cell in involved tissues implicate this virus as an associated etiologic agent. Restriction fragment length polymorphism (RFLP) and cytogenetic analysis of involved tissue demonstrated donor origin (five of seven) or host origin (two of seven). Histologic appearance was similar to EBV-induced polymorphic B cell proliferations described following solid organ transplantation, or which occur de novo in primary immunodeficiency. Six of seven patients with adequate tissue available for study were found to have monoclonal proliferations by: in situ immunofluorescence (six of seven), and/or immunoglobulin gene rearrangement, (four of six). Cytogenetic analysis of involved tissues from four patients showed a normal karyotype, whereas two had multiple clonal chromosomal abnormalities. Seven patients died despite aggressive attempts at therapy with combinations of antiviral, immunologic, and chemotherapeutic agents. 相似文献
102.
V. PÖNITZ T. BRÜGGER‐ANDERSEN D. PRITCHARD H. GRUNDT H. STAINES D. W. T. NILSEN FOR THE RACS STUDY GROUP 《Journal of thrombosis and haemostasis》2009,7(2):277-287
Summary. Background: We assessed the relation between admission levels of activated factor XII type A (XIIaA), and long‐term all‐cause and cardiac mortality and recurrent troponin T (TnT) positive cardiovascular events in a consecutive cohort of 870 patients admitted with a clinically strongly suspected acute coronary syndrome (ACS). Methods and results: After a 24‐month follow‐up period, 138 patients (15.8%) had died and 155 (17.8%) had suffered from a recurrent TnT positive (TnT > 0.05 ng mL?1) event. XIIaA levels were significantly lower in long‐term survivors than in patients who died (22.9 (17.7–32.1) vs. 27.2 (20.0–39.7) pmol L?1 [median, 25 and 75% percentiles], P < 0.001). The unadjusted hazard ratio for death within 2 years in patients with XIIaA in the highest quartile was 2.49 (95% confidence interval (CI), 1.52–4.06) as compared with patients with XIIaA in the lowest quartile. In a stepwise Cox regression model for death within 2 years, XIIaA added prognostic information for all‐cause mortality (HR 2.05; 95% CI, 1.21–3.47) above and beyond age, a history of heart failure, ST‐segment elevation, TnT and B‐type natriuretic peptide (BNP). In the subgroup of patients with an admission TnT ≤ 0.05 ng mL?1, XIIaA provided independent prognostic information for all‐cause mortality (HR 3.88; 95% CI, 1.66–9.08) and for the combined endpoint of death or recurrent TnT positive event (HR 2.46; 95% CI, 1.34–4.50). Conclusion: XIIaA, a recently identified in vivo form of activated factor XII is an independent indicator of long‐term all‐cause mortality in patients admitted with chest pain, providing prognostic information above and beyond conventional risk factors. 相似文献
103.
In vitro characteristics of white cell-reduced single-unit platelet concentrates stored in syringes 总被引:1,自引:0,他引:1
PT Pisciotto ; EL Snyder ; JA Snyder ; S Frattaroli ; SM Hopfer ; HM Rinder ; BR Smith 《Transfusion》1994,34(5):407-411
BACKGROUND: Platelet concentrates (PCs) for premature infants may be subjected to filtration, centrifugation, and various storage conditions before transfusion. STUDY DESIGN AND METHODS: As there are few data on the cumulative effect of these procedures on PCs, platelet properties (including biochemical and functional in vitro assays) were evaluated after the processing of single units of PCs through a 1-unit-capacity high-efficiency white cell (WBC)-reduction filter followed by syringe storage at either 22 or 37 degrees C for 6 hours. Two- and 5-day-old PCs, volume-reduced PCs, and prestorage WBC-reduced PCs were evaluated. RESULTS: WBC filtration consistently resulted in a 3 to 4 log10 reduction in WBCs, with less than 15-percent platelet loss. No adverse effects of platelet function or evidence of increased platelet activation as determined by the percentage of P-selectin positivity were noted. A decrease in pH associated with increased lactate production and consumption of glucose was observed following syringe storage under all conditions tested. Such changes were most pronounced, however, with volume-reduced PCs stored at 37 degrees C (pH 6.31 +/− 0.15, lactate 23.0 +/− 3.06 mmol/L). All pH levels at the end of storage were above the minimum Food and Drug Administration requirement (pH 6.0). CONCLUSION: The in vitro data suggest that single units of PCs can undergo WBC filtration followed by syringe storage for up to 6 hours and still maintain acceptable storage characteristics. The practice of maintaining volume-reduced PCs in syringes for 6 hours at 37 degrees C in isolettes during transfusion should, however, be avoided. 相似文献
104.
Selection of platelets for refractory patients by HLA matching and prospective crossmatching 总被引:2,自引:0,他引:2
G Moroff ; G Garratty ; JM Heal ; BR MacPherson ; D Stroncek ; ST Huang ; W Ho ; LD Petz ; MF Leach ; SS Lennon ; et al. 《Transfusion》1992,32(7):633-640
A multi-site clinical study compared platelets chosen for refractory patients by prospective platelet crossmatching using stored donor platelets and HLA-based selection. Seventy-three patients who were refractory to random-donor platelets received two plateletpheresis components, one chosen by HLA-based criteria and the other by crossmatching. Patients were carefully evaluated to exclude nonimmune factors that could adversely affect transfusion results. Each of the five study sites used a crossmatch procedure with which it had experience. Results from this study indicate the following: 1) The overall rate of successful transfusion was similar when an HLA-based method of donor selection that includes all grades of matching and mismatching was compared to a crossmatch-based method of donor selection. 2) HLA-based selection that restricts recipients to grade A and BU matches was superior to a selection method based upon crossmatching alone. Donor selection based on HLA matching (grades A or BU) was also superior to selection based on any degree of HLA mismatching (grades BX, C, or D). 3) Selection of donors based on HLA-cross-reactive groups (defined by in vitro serologic crossreactivity) was no more successful than that based on grade C and D mismatches and was no more successful than selection by crossmatching alone. 4) Lymphocytotoxic and platelet antibodies were not detected in many of the enrolled patients, even though patients demonstrating nonimmune factors were eliminated from the study. It can be concluded that HLA-compatible (grades A and BU) platelets provide optimal support for refractory patients, but that crossmatch-selected platelets are acceptable as an alternative component. 相似文献
105.
TheFirstWorldChineseCongresofDigestionwasheldinBeijingfromOctober20to22,1998inthebeautifulcapitalcityofBeijing.Thespecificaim... 相似文献
106.
Atlas R Campbell P Cozzarelli NR Curfman G Enquist L Fink G Flanagin A Fletcher J George E Hammes G Heyman D Inglesby T Kaplan S Kennedy D Krug J Levinson RE Marcus E Metzger H Morse SS O'Brien A Onderdonk A Poste G Renault B Rich R Rosengard A Salzberg S Salzburg S Scanlan M Shenk T Tabor H Varmus H Wimmer E Yamamoto K;Journal Editors Authors Group 《Proceedings of the National Academy of Sciences of the United States of America》2003,100(4):1464
107.
We tested whether the in vivo infusion of recombinant, soluble CTLA4 fused with Ig heavy chains, as a surrogate ligand used to block CD28/CTLA4 T-cell costimulation, could prevent efficient T-cell activation and thereby reduce graft-versus-host disease (GVHD). Lethally irradiated B10.BR recipients of major histocompatibility complex disparate C57BL/6 donor grafts received intraperitoneal injections of human CTLA4-Ig (hCTLA4-Ig) or murine CTLA4-Ig (mCTLA4-Ig) in various doses and schedules beginning on day -1 or day 0 of bone marrow transplantation (BMT). In all five experiments, recipients of CTLA4-Ig had a significantly higher actuarial survival rate compared to mice injected with an irrelevant antibody control (L6) or saline alone. Survival rates in recipients of hL6 or PBS were 0% at 29 to 45 days post-BMT. In recipients of CTLA4-Ig, survival rates were as high as 63% mice surviving 3 months post-BMT. However, protection was somewhat variable and recipients of CTLA4-Ig were not GVHD-free by body weight, clinical appearance, and histopathologic examination. There were no significant differences in the survival rates in comparing injection dose, injection duration, or species of CTLA4-Ig (hCTLA4-Ig v mCTLA4- Ig). Splenic and peripheral blood flow cytometry studies of long-term hCTLA4-Ig-injected survivors showed a significant peripheral B-cell and CD4+ T-cell lymphopenia, consistent with GVHD. A kinetic study of splenic reconstitution was performed in mice that received hCTLA4-Ig and showed that mature splenic localized CD8+ T-cell repopulation was not significantly different in recipients of hCTLA4-Ig compared with hL6, despite the significant increase in actuarial survival rate in that experiment. These data suggest that the beneficial effect of hCTLA4-Ig on survival is not mediated by interfering with mature donor- derived T-cell repopulation post-BMT. Neither hCTLA4-Ig nor mCTLA4-Ig interfered with hematopoietic recovery post-BMT. We conclude that CTLA4- Ig (most likely in combination with other agents) may represent an important new modality for GVHD prevention. 相似文献
108.
A comparison between activated protein C and des-1-41-light chain- activated protein C in reactions with type 1 plasminogen activator inhibitor 总被引:2,自引:0,他引:2
This study investigates the role of the gamma-carboxyglutamic acid (gla) containing domain of activated protein C in interactions with both platelet-derived and purified type 1 plasminogen activator inhibitor (PAI-1). The activity of human platelet PAI-1 was neutralized to the same extent by bovine activated protein C and bovine des-1-41- light chain-activated protein C. Both forms of activated protein C formed SDS-stable, divalent-cation independent complexes with platelet PAI-1, as demonstrated by immunoblotting using antibodies directed to either protein C or PAI-1. Since activated protein C neutralized PAI-1, the potential inhibition of the enzyme by PAI-1 was studied. Purified PAI-1 inhibited the amidolytic activity of bovine-activated protein C and bovine des-1-41-light chain-activated protein C with a k2 of 2.85 X 10(4) M-1 sec-1 for both proteins. These data suggest that the gla domain of activated protein C is not required for neutralization of PAI- 1 activity, for complex formation with PAI-1, or for inhibition of the amidolytic activity of activated protein C by PAI-1. 相似文献
109.
A fusion protein was synthesized consisting of the murine granulocyte- macrophage colony-stimulating factor (mGM-CSF) gene spliced to a truncated form of the diphtheria toxin (DT390) gene coding for a molecule that retained full enzymatic activity, but excluded the native binding domain. The DT390-mGM-CSF hybrid gene was cloned into a vector under the control of an inducible promoter and the protein expressed in Escherichia coli. After induction, a protein was purified from inclusion bodies in accord with the deduced molecular weight of DT390 mGM-CSF. Cell-free studies of the adenosine diphosphate-ribosylating activity of DT390 mGM-CSF showed results that were similar to those of native DT. The DT390 mGM-CSF immunotoxin inhibited FDCP2.1d, a murine myelomonocytic tumor line expressing the GM-CSF receptor with an IC50 (concentration inhibiting 50% activity) of 5 x 10(-11) mol/L. The fusion toxin was specifically cytotoxic and directed by the GM-CSF portion of the molecule because addition of a monoclonal antibody directed against GM-CSF inhibited its ability to kill the cell line. Cell lines that do not express GM-CSF receptor were not inhibited by the fusion toxin. DT390 mGM-CSF was also able to specifically inhibit normal committed bone marrow (BM) progenitor cells as measured in clonal colony-forming unit granulocyte-macrophage assays. Together, these findings indicate that DT390 mGM-CSF may be useful as a novel tool for purging BM of contaminating leukemia cells or in vivo for eliminating residual leukemia cells. Also, it can be used to determine whether committed and/or noncommitted BM progenitor cells express the GM-CSF receptor. 相似文献
110.
Rakesh Mehra Kushaljit Singh Sodhi Akshay Saxena BR Thapa Niranjan Khandelwal 《Gut and liver》2015,9(3):388-394